

December 31, 2001 and subsequent Quarterly Reports on Form 10-Q. There is no assurance that such development efforts will succeed, that such products will receive required regulatory clearance or that, even if such regulatory clearance were received, such products would ultimately achieve commercial success. Copies of Medarex's public disclosure filings are available through the investor relations department.

Medarex(R), the Medarex logo, UltiMAB(TM) and UltiMAB Human Antibody Development System(SM) are trademarks and service marks of Medarex, Inc. All rights are reserved.

MAKE YOUR OPINION COUNT - [Click Here](#)

<http://tbutton.prnewswire.com/prn/11690X08778055>

SOURCE Medarex, Inc.

Web site: <http://www.medarex.com>

CONTACT: Laura S. Choi, Investor Relations, +1-609-430-2880, x216, or
Mantuano, Corporate Communications (media), +1-609-430-2880, x221, both
Medarex

Company News On-Call: <http://www.prnewswire.com/gh/cnoc/comp/108265.htm>

©2001-2003 Medarex, Inc. All rights reserved. - Legal Disclaimer - Trademarks